- Home
- HYPR vs COEP Comparison
HYPR vs COEP Comparison
Compare HYPR & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HYPR | COEP |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | United States |
| Employees | N/A | 6 |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 109.7M | 91.2M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | HYPR | COEP |
|---|---|---|
| Price | $1.66 | $16.40 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $1.59 | N/A |
| AVG Volume (30 Days) | ★ 739.5K | 92.3K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.21 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,563,000.00 | N/A |
| Revenue This Year | $50.75 | N/A |
| Revenue Next Year | $29.71 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.22 | N/A |
| 52 Week Low | $0.58 | $6.80 |
| 52 Week High | $2.22 | $21.41 |
Technical Indicators
Market Signals| Indicator | HYPR | COEP |
|---|---|---|
| Relative Strength Index (RSI) | 59.94 | 72.18 |
| Support Level | $1.04 | $13.77 |
| Resistance Level | $1.94 | $19.19 |
| Average True Range (ATR) | 0.10 | 1.15 |
| MACD | -0.02 | 0.47 |
| Stochastic Oscillator | 64.04 | 87.62 |
Price Performance
Historical ComparisonAbout HYPR Hyperfine Inc.
Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales which consist of sales from subscriptions of bundled devices, maintenance, and software.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical and technology company. The biopharmaceutical division focuses on developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its research and development efforts. The technology division focuses on enhancing operational capabilities through technologies. This division features AI-powered marketing software and robotic process automation tools designed to optimize business processes and improve overall efficiency. It derives the majority of the revenue from the Technology segment.